IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up
by Zacks Equity Research
IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 36.63% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Stock Moves -0.66%: What You Should Know
by Zacks Equity Research
In the latest trading session, Idexx Laboratories (IDXX) closed at $548.99, marking a -0.66% move from the previous day.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Zimmer Biomet (ZBH) Enhances ZBEdge Portfolio With Latest Suite
by Zacks Equity Research
Zimmer Biomet's (ZBH) latest portfolio enhancement is aimed at improving patient outcome throughout the entire treatment process.
Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays
by Zacks Equity Research
Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on its slew of product launches and regulatory approvals.
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
by Urmimala Biswas
We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) fiscal second-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.
Reasons to Hold on to Syneos Health (SYNH) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness is worrisome.
BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test
by Zacks Equity Research
BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.
Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed
by Zacks Equity Research
Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed
Late-Breaking Data Supports Boston Scientific's (BSX) TheraSphere
by Zacks Equity Research
Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.
Here's Why You Should Retain Henry Schein (HSIC) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on robust sales of PPE and COVID-19-related products.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to gain traction on a solid product portfolio and strong international exposure. However, stiff competition is worrisome.
OPKO Health (OPK) BioReference Extends COVID-19 School Testing
by Zacks Equity Research
OPKO Health's (OPK) BioReference expands COVID-19 testing in schools to create a safer learning environment for students, teachers, staff and their families.
3 Top Medical Instruments Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Instruments industry. NTUS, IDXX and HOLX are well positioned to gain.
AmerisourceBergen (ABC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AmerisourceBergen (ABC) is optimistic about maintaining a robust segmental performance amid the pandemic-led business disruptions.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain traction for solid product portfolio and improving margins. However, forex is a woe
5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic
by Debanjana Dey
Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.
Zacks.com featured highlights include: Toll Brothers, Goldman Sachs, Owens Corning, CBRE Group and IDEXX Laboratories
by Zacks Equity Research
Zacks.com featured highlights include: Toll Brothers, Goldman Sachs, Owens Corning, CBRE Group and IDEXX Laboratories
5 Best Stocks Likely to Beat Earnings Estimates
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom lines in their next releases.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.